Value2022202320242025TTMSelling/general/admin expenses6.14 M9.07 M6.95 M9.72 M9.72 MResearch & development8.93 M11.11 M10.01 M453.75 K14.55 MOperating income-16.18 M-20.18 M-16.96 M-24.27 M-24.27 MNon-Operating Income, Total1 87034.49 K318.37 K313.95 K313.95 KInterest expense, net of interest capitalized6 9676 86357——Non-Operating Income, excl. Interest Expenses-5 09727.63 K318.31 K0161.88 KUnusual income/expense———313.95 K—Pretax income-15.8 M-19.8 M-23.3 M-22.39 M-42.1 MEquity in earnings—————Taxes-1.2 M-4.1 M-4.8 M2 0002 000Non-controlling/minority interest-74.33 K————After tax other income/expense—————Net income before discontinued operations-15.77 M-19.77 M-23.25 M-22.4 M-22.4 MDiscontinued operations—————Net income-15.77 M-19.77 M-23.25 M-22.4 M-22.4 MDilution adjustment—————Preferred dividends—————Diluted net income available to common stockholders-16.22 M-19.77 M-23.25 M-22.4 M-22.4 MBasic earnings per share (Basic EPS)-1.75-1.49-1.05-0.7-0.7Diluted earnings per share (Diluted EPS)-1.75-1.49-1.05-0.7-0.7Average basic shares outstanding9.28 M13.26 M22.2 M32.11 M123.31 MDiluted shares outstanding9.28 M13.26 M22.2 M32.11 M123.31 MEBITDA—————EBIT-16.18 M-20.18 M-16.96 M——Cost of revenue—————Other cost of goods sold—————Depreciation & amortization (cash flow)—————
MAIA Biotechnology Inc
MAIA Biotechnology, Inc. is a public, immune-oncology company based in Chicago, IL focused on the development of telomere targeting agents for the treatment of telomerase-positive cancer cells.